Literature DB >> 15047808

EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance.

Alexey V Gordadze1, Chisaroka W Onunwor, RongSheng Peng, David Poston, Elisabeth Kremmer, Paul D Ling.   

Abstract

Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2), a direct transcriptional activator of viral and cellular genes, is required for EBV-induced B-cell transformation. The functional role of conserved regions within the amino terminus of the protein preceding the poly-proline region has yet to be fully characterized. Thus, we tested whether the EBNA2 amino-terminal 30 amino acid residues, containing evolutionarily conserved region 1, are required for stimulating viral and cellular gene expression necessary for B-cell transformation in a viral transcomplementation assay. We found that these residues are required for its ability to induce LMP-1 expression in lymphoblastoid cell lines (LCLs), to stimulate LMP-1 promoter reporter plasmids in transient-cotransfection assays, and to rescue LCL growth following inactivation of endogenous wild-type EBNA2 protein. Deletion of amino acid residues 3 to 30 also impaired its ability to self-associate in coimmunoprecipitation assays. These data indicate that EBNA2 residues 3 to 30 comprise an essential domain required for induction of LMP-1 expression and, consequently, for maintenance of the immortalized phenotype of LCLs. The ability to self-associate into dimers or multimers conferred by this domain may be an important mechanism for these effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047808      PMCID: PMC374290          DOI: 10.1128/jvi.78.8.3919-3929.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.

Authors:  R Longnecker; C L Miller; X Q Miao; A Marchini; E Kieff
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Residues 231 to 280 of the Epstein-Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation.

Authors:  S Harada; R Yalamanchili; E Kieff
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

3.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.

Authors:  K M Kaye; K M Izumi; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

4.  The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2.

Authors:  C Kaiser; G Laux; D Eick; N Jochner; G W Bornkamm; B Kempkes
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Functional replacement of the intracellular region of the Notch1 receptor by Epstein-Barr virus nuclear antigen 2.

Authors:  T Sakai; Y Taniguchi; K Tamura; S Minoguchi; T Fukuhara; L J Strobl; U Zimber-Strobl; G W Bornkamm; T Honjo
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

6.  Transcriptional activation signals found in the Epstein-Barr virus (EBV) latency C promoter are conserved in the latency C promoter sequences from baboon and Rhesus monkey EBV-like lymphocryptoviruses (cercopithicine herpesviruses 12 and 15).

Authors:  E M Fuentes-Pananá; S Swaminathan; P D Ling
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

7.  Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B.

Authors:  R Longnecker; C L Miller; B Tomkinson; X Q Miao; E Kieff
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  EBNA-2 of herpesvirus papio diverges significantly from the type A and type B EBNA-2 proteins of Epstein-Barr virus but retains an efficient transactivation domain with a conserved hydrophobic motif.

Authors:  P D Ling; J J Ryon; S D Hayward
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro.

Authors:  R Longnecker; C L Miller; X Q Miao; B Tomkinson; E Kieff
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Epstein-Barr virus (EBV) nuclear-antigen-2-induced up-regulation of CD21 and CD23 molecules is dependent on a permissive cellular context.

Authors:  M Cordier-Bussat; M Billaud; A Calender; G M Lenoir
Journal:  Int J Cancer       Date:  1993-01-02       Impact factor: 7.396

View more
  12 in total

1.  The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter.

Authors:  Rongsheng Peng; Stephanie C Moses; Jie Tan; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Hsp72 up-regulates Epstein-Barr virus EBNALP coactivation with EBNA2.

Authors:  Chih-Wen Peng; Bo Zhao; Hong-Chi Chen; Min-Luen Chou; Chiou-Yan Lai; Shinn-Zong Lin; Hsue-Yin Hsu; Elliott Kieff
Journal:  Blood       Date:  2007-03-06       Impact factor: 22.113

3.  Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.

Authors:  Chong Wang; Hufeng Zhou; Yong Xue; Jun Liang; Yohei Narita; Catherine Gerdt; Amy Y Zheng; Runsheng Jiang; Stephen Trudeau; Chih-Wen Peng; Benjamin E Gewurz; Bo Zhao
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

4.  PU.1-dependent regulation of UCH L1 expression in B-lymphoma cells.

Authors:  Anjali Bheda; Wei Yue; Anuradha Gullapalli; Julia Shackelford; Joseph S Pagano
Journal:  Leuk Lymphoma       Date:  2011-04-20

5.  Nuclear-cytoplasmic shuttling is not required for the Epstein-Barr virus EBNA-LP transcriptional coactivation function.

Authors:  Paul D Ling; Jie Tan; RongSheng Peng
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

6.  Regulation of Sp100A subnuclear localization and transcriptional function by EBNA-LP and interferon.

Authors:  Chisaroka W Echendu; Paul D Ling
Journal:  J Interferon Cytokine Res       Date:  2008-11       Impact factor: 2.607

7.  The nuclear chaperone nucleophosmin escorts an Epstein-Barr Virus nuclear antigen to establish transcriptional cascades for latent infection in human B cells.

Authors:  Cheng-Der Liu; Ya-Lin Chen; Yi-Li Min; Bo Zhao; Chi-Ping Cheng; Myung-Soo Kang; Shu-Jun Chiu; Elliott Kieff; Chih-Wen Peng
Journal:  PLoS Pathog       Date:  2012-12-13       Impact factor: 6.823

8.  C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7.

Authors:  Laila Cancian; Rachel Bosshard; Walter Lucchesi; Claudio Elgueta Karstegl; Paul J Farrell
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

9.  The EBNA-2 N-Terminal Transactivation Domain Folds into a Dimeric Structure Required for Target Gene Activation.

Authors:  Anders Friberg; Sybille Thumann; Janosch Hennig; Peijian Zou; Elfriede Nössner; Paul D Ling; Michael Sattler; Bettina Kempkes
Journal:  PLoS Pathog       Date:  2015-05-29       Impact factor: 6.823

10.  Species-specific functions of Epstein-Barr virus nuclear antigen 2 (EBNA2) reveal dual roles for initiation and maintenance of B cell immortalization.

Authors:  Janine Mühe; Fred Wang
Journal:  PLoS Pathog       Date:  2017-12-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.